---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-010958"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:14:05.393866+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# KALA BIO reports Q2 net loss of $9.6M, cash $54.2M; Phase 2b data due Q1 2025

## Summary
- Net loss of $9.6M ($3.16 per share) for Q2 2024 vs. $10.4M ($4.36 per share) a year ago.
- Cash and equivalents $54.2M at June 30, 2024; with CIRM award, runway expected into Q4 2025.
- Closed $12.5M private placement led by SR One; net proceeds of $12.3M.
- Topline results from Phase 2b CHASE trial of KPI-012 for PCED targeted in Q1 2025.
- R&D expenses rose to $5.3M from $4.3M on higher KPI-012 development costs.

## SEC filing metadata
- accession: 0001558370-24-010958
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837024010958/0001558370-24-010958-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837024010958/kala-20240806x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-010958
- JSON: https://secwatch.observer/filing/0001558370-24-010958.json
- Plain text: https://secwatch.observer/filing/0001558370-24-010958.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.